138 related articles for article (PubMed ID: 9436820)
1. Phosphodiesterases in the rat renal vasculature.
Jackson EK; Mi Z; Carcillo JA; Gillespie DG; Dubey RK
J Cardiovasc Pharmacol; 1997 Dec; 30(6):798-801. PubMed ID: 9436820
[TBL] [Abstract][Full Text] [Related]
2. Characterization of renal ecto-phosphodiesterase.
Jackson EK; Ren J; Zacharia LC; Mi Z
J Pharmacol Exp Ther; 2007 May; 321(2):810-5. PubMed ID: 17308037
[TBL] [Abstract][Full Text] [Related]
3. Regulation of renovascular adenosine 3',5'-cyclic monophosphate in spontaneously hypertensive rats.
Jackson EK; Mi Z
Hypertension; 2009 Aug; 54(2):270-7. PubMed ID: 19528365
[TBL] [Abstract][Full Text] [Related]
4. Regulation of 3',5'-cAMP in preglomerular smooth muscle and endothelial cells from genetically hypertensive rats.
Cheng D; Ren J; Gillespie DG; Mi Z; Jackson EK
Hypertension; 2010 Dec; 56(6):1096-101. PubMed ID: 20975032
[TBL] [Abstract][Full Text] [Related]
5. OPC-13013, a cyclic nucleotide phosphodiesterase type III, inhibitor, inhibits cell proliferation and transdifferentiation of cultured rat hepatic stellate cells.
Shimizu E; Kobayashi Y; Oki Y; Kawasaki T; Yoshimi T; Nakamura H
Life Sci; 1999; 64(23):2081-8. PubMed ID: 10372650
[TBL] [Abstract][Full Text] [Related]
6. Effects of a cardiotonic quinolinone derivative Y-20487 on the isoproterenol-induced positive inotropic action and cyclic AMP accumulation in rat ventricular myocardium: comparison with rolipram, Ro 20-1724, milrinone, and isobutylmethylxanthine.
Katano Y; Endoh M
J Cardiovasc Pharmacol; 1992; 20(5):715-22. PubMed ID: 1280732
[TBL] [Abstract][Full Text] [Related]
7. Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells.
Pan X; Arauz E; Krzanowski JJ; Fitzpatrick DF; Polson JB
Biochem Pharmacol; 1994 Aug; 48(4):827-35. PubMed ID: 7521642
[TBL] [Abstract][Full Text] [Related]
8. Selective effects of phosphodiesterase inhibitors on different phosphodiesterases, adenosine 3',5'-monophosphate metabolism, and lipolysis in 3T3-L1 adipocytes.
Elks ML; Manganiello VC
Endocrinology; 1984 Oct; 115(4):1262-8. PubMed ID: 6207009
[TBL] [Abstract][Full Text] [Related]
9. Two mechanisms of inhibition by prostaglandin E2 of hormone-dependent cell cAMP in the rat collecting tubule.
Chabardès D; Montégut M; Zhou Y; Siaume-Perez S
Mol Cell Endocrinol; 1990 Oct; 73(2-3):111-21. PubMed ID: 1702742
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of phosphodiesterase inhibitors on accumulation of cyclic AMP in isolated ventricular cardiomyocytes.
Kelso EJ; McDermott BJ; Silke B
Biochem Pharmacol; 1995 Feb; 49(4):441-52. PubMed ID: 7872950
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of chemotactic peptide-induced neutrophil adhesion to vascular endothelium by cAMP modulators.
Derian CK; Santulli RJ; Rao PE; Solomon HF; Barrett JA
J Immunol; 1995 Jan; 154(1):308-17. PubMed ID: 7995950
[TBL] [Abstract][Full Text] [Related]
12. Regulation of isoproterenol-induced cyclic AMP accumulation in LRM55 glial cells by phosphodiesterase.
Madelian V; Shain W
J Pharmacol Exp Ther; 1987 Nov; 243(2):618-23. PubMed ID: 2445955
[TBL] [Abstract][Full Text] [Related]
13. Cyclic AMP-specific phosphodiesterase inhibitor rolipram and RO-20-1724 promoted apoptosis in HL60 promyelocytic leukemic cells via cyclic AMP-independent mechanism.
Zhu WH; Majluf-Cruz A; Omburo GA
Life Sci; 1998; 63(4):265-74. PubMed ID: 9698035
[TBL] [Abstract][Full Text] [Related]
14. Differential inhibition of human neutrophil functions. Role of cyclic AMP-specific, cyclic GMP-insensitive phosphodiesterase.
Wright CD; Kuipers PJ; Kobylarz-Singer D; Devall LJ; Klinkefus BA; Weishaar RE
Biochem Pharmacol; 1990 Aug; 40(4):699-707. PubMed ID: 1696820
[TBL] [Abstract][Full Text] [Related]
15. Evidence for an endogenous cAMP-adenosine pathway in the rat kidney.
Mi Z; Jackson EK
J Pharmacol Exp Ther; 1998 Dec; 287(3):926-30. PubMed ID: 9864274
[TBL] [Abstract][Full Text] [Related]
16. Effects of selective phosphodiesterase inhibitors on the polymorphonuclear leukocyte respiratory burst.
Nielson CP; Vestal RE; Sturm RJ; Heaslip R
J Allergy Clin Immunol; 1990 Nov; 86(5):801-8. PubMed ID: 1977788
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the phosphodiesterase inhibition by 2-(3-methoxy-5-methylsulfinyl-2-thienyl)-1H-imidazo-(4,5-c)-pyridine HCl and its sulfide- and sulfone derivatives in myocardial preparations from failing human hearts.
Bethke T; Klimkiewicz A; Meyer W; Schumacher C; Schmitz W; Scholz H; Starbatty J; Wenzlaff H; Zimmermann W
Arzneimittelforschung; 1995 Jul; 45(7):771-6. PubMed ID: 8573220
[TBL] [Abstract][Full Text] [Related]
18. Effects of type-selective phosphodiesterase inhibitors on glucose-induced insulin secretion and islet phosphodiesterase activity.
Shafiee-Nick R; Pyne NJ; Furman BL
Br J Pharmacol; 1995 Aug; 115(8):1486-92. PubMed ID: 8564209
[TBL] [Abstract][Full Text] [Related]
19. Role of cyclic nucleotide phosphodiesterase isoforms in cAMP compartmentation following beta2-adrenergic stimulation of ICa,L in frog ventricular myocytes.
Jurevicius J; Skeberdis VA; Fischmeister R
J Physiol; 2003 Aug; 551(Pt 1):239-52. PubMed ID: 12815180
[TBL] [Abstract][Full Text] [Related]
20. Metabolism of cAMP to adenosine in the renal vasculature.
Jackson EK; Mi Z; Gillespie DG; Dubey RK
J Pharmacol Exp Ther; 1997 Oct; 283(1):177-82. PubMed ID: 9336322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
